Last10K.com

Rhythm Pharmaceuticals, Inc. (RYTM) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

Rhythm Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1649904 Ticker: RYTM
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Mar. 01, 2019
Jun. 29, 2018
Document and Entity Information   
Entity Registrant NameRHYTHM PHARMACEUTICALS, INC.  
Entity Central Index Key0001649904  
Document Type10-K  
Document Period End DateDec. 31, 2018  
Amendment Flagfalse  
Current Fiscal Year End Date--12-31  
Entity Well-known Seasoned IssuerYes  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Filer CategoryAccelerated Filer  
Entity Small Businessfalse  
Entity Emerging Growth Companytrue  
Entity Shell Companyfalse  
Entity Ex Transition Periodtrue  
Entity Public Float  $ 640.8
Entity Common Stock, Shares Outstanding 34,425,830 
Document Fiscal Year Focus2018  
Document Fiscal Period FocusFY  

View differences made from one year to another to evaluate Rhythm Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Rhythm Pharmaceuticals, Inc..

Continue

Assess how Rhythm Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Rhythm Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (Deficit)
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (Deficit) (Parenthetical)
Consolidated Statements Of Operations And Comprehensive Loss
Accrued Expenses
Accrued Expenses (Details)
Accrued Expenses (Tables)
Commitments And Contingencies
Commitments And Contingencies (Details)
Commitments And Contingencies (Tables)
Fair Value Of Financial Assets And Liability
Fair Value Of Financial Assets And Liability (Details)
Fair Value Of Financial Assets And Liability (Tables)
Fair Value Of Financial Assets And Liability - Financial Liabilities (Details)
Fair Value Of Financial Assets And Liability - Marketable Securities (Details)
Income Tax
Income Tax (Tables)
Income Tax - Deferred Tax Assets (Details)
Income Tax - Operating Loss Carryforward (Details)
Income Tax - Reconciliation Of Income Tax Rate (Details)
Income Tax - Tax Cuts And Jobs Act (Details)
Nature Of Business
Nature Of Business (Details)
Preferred And Common Stock (Details)
Preferred Stock And Common Stock
Related-Party Transactions
Related-Party Transactions (Details)
Selected Quarterly Financial Data (Unaudited)
Selected Quarterly Financial Data (Unaudited) (Details)
Selected Quarterly Financial Data (Unaudited) (Tables)
Significant Agreements
Significant Agreements (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - 2017 Equity Incentive Plan (Details)
Stock-Based Compensation - Common Stock Option Activity (Details)
Stock-Based Compensation - Compensation Expense (Details)
Stock-Based Compensation - Llc Incentive Plan (Details)
Stock-Based Compensation - Range Of Exercise Prices (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Details)
Summary Of Significant Accounting Policies - Government Grants (Details)
Summary Of Significant Accounting Policies - Net Loss Per Share (Details)
Summary Of Significant Accounting Policies - Property, Plant And Equipment (Details)
Summary Of Significant Accounting Policies - Shares Excluded For Eps (Details)
Ticker: RYTM
CIK: 1649904
Form Type: 10-K Annual Report
Accession Number: 0001558370-19-001698
Submitted to the SEC: Fri Mar 08 2019 9:56:50 AM EST
Accepted by the SEC: Fri Mar 08 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rytm/0001558370-19-001698.htm